

- g) a specifically named antigen specific immune response that is a mucosal immune response;
- h) a specifically named therapeutic agent that is an anti-viral agent; and
- i) a specifically named antigen that is a viral antigen.

Applicants have not elected species for claims 22 and 23, as these claims are not consistent with a mucosal route of administration. In a telephone conversation with the Examiner on April 29, 2002, the Examiner clarified that the election of a specifically named antigen specific immune response was to be made between a systemic immune response (claim 20) and a mucosal immune response (claims 21). Accordingly, Applicants have elected a mucosal immune response (as indicated above).

REMARKS

In response to the Restriction Requirement, Applicants have elected Group I and specific species with traverse. The traversal is made on the grounds that a search and examination of all the pending claims would not require an undue burden of searching. Having made this election, Applicants expressly reserve the right to file one or more divisional applications on the subject matter of the non-elected claims.

Respectfully submitted,



Maria A. Trevisan, Reg. No. 48,207
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, MA 02210
Telephone (617) 720-3500

Docket No. C1040/7010 (HCL/MAT)

Dated: May 7, 2002

X05/09/02